# Jeffrey Schultz Appears on Bloomberg Intelligence Votes and Verdicts Podcast > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/jeffrey-schultz-appears-on-bloomberg-intelligence-votes-and-verdicts-podcast/ > **Published:** 2026-06-22T12:15:23-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T16:59:04-04:00 > **Clinical Summary:** Understanding cannabis rescheduling federal policy implications for clinical practice, research access, and patient care in medical settings. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchTHCIndustrySafetyPainAnxiety Why This Matters Clinicians need to understand marijuana rescheduling implications because it directly affects their legal ability to recommend cannabis, access to [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) data, and insurance coverage for patients who may benefit therapeutically. Changes in federal scheduling could expand legitimate medical use pathways while potentially improving data collection on efficacy and safety outcomes that currently remain limited due to Schedule I restrictions. Patients may gain clearer guidance on evidence-based cannabis use and better access to quality-controlled products once scheduling barriers are reduced. Clinical Summary This podcast discussion examines the current landscape of cannabis rescheduling and its potential implications for medical practice. The speaker addresses both state-level medical marijuana licensing and federal rescheduling efforts, which could significantly expand access to cannabis as a therapeutic option and potentially facilitate [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) that has long been constrained by Schedule I restrictions. Federal rescheduling would likely enable greater standardization of products, improved quality control, and the ability to conduct rigorous [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) to establish efficacy and safety profiles for specific indications. These regulatory changes would also affect insurance coverage, prescription documentation, and clinician liability considerations. For clinicians managing patients interested in cannabis therapeutics, understanding the evolving regulatory landscape is essential, as rescheduling would transform cannabis from a legal gray area into a more formally recognized medication subject to conventional pharmaceutical oversight and evidence standards. Clinical Perspective 🏥 The ongoing debate around cannabis rescheduling reflects a widening gap between federal prohibition and state-level medical authorization that directly affects clinical practice and patient care. While rescheduling from Schedule I could facilitate research and reduce regulatory barriers for healthcare providers, clinicians should recognize that such policy changes do not automatically resolve fundamental questions about efficacy, optimal dosing, drug interactions, or long-term safety—evidence gaps that persist regardless of scheduling status. The distinction between state-licensed [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) and federally compliant pharmaceutical cannabinoids adds further complexity, as products available through state programs often lack the standardization and rigorous testing that inform conventional prescribing decisions. For practitioners, the practical implication is that rescheduling alone will not substitute for the careful clinical judgment, patient education, and ongoing research engagement needed to responsibly discuss cannabis with patients; instead, providers should prepare to help patients navigate an evolving landscape by staying informed about emerging evidence while maintaining 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Jeffrey%20Schultz%20Appears%20on%20Bloomberg%20Intelligence%20Votes%20and%20Verdicts%20Podcast%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D64062)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D64062)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Jeffrey%20Schultz%20Appears%20on%20Bloomberg%20Intelligence%20Votes%20and%20Verdicts%20Podcast%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D64062)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://foleyhoag.com/news-and-insights/media-center/2026/june/jeffrey-schultz-appears-on-bloomberg-intelligence-votes-and-verdicts-podcast/](https://foleyhoag.com/news-and-insights/media-center/2026/june/jeffrey-schultz-appears-on-bloomberg-intelligence-votes-and-verdicts-podcast/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).